Clarrio.ai / Whitepapers
Scientific perspectives on real-world data, real-world evidence (RWE), longevity programs and evidence workflows, focused on the questions behind the data, not just the technology that collects it.
Published · White paper 02
How sponsors, CROs and research teams can capture what happens to patients between visits, and turn real-world data into evidence that is fit for its intended use.
Proposed editorial selection
These are proposed topics, not yet published Clarrio.ai papers. The final library will follow the documents supplied and approved for publication. No downloads, authors, findings or publication dates are claimed yet.
6 proposed topics · documents forthcoming
Longevity
From periodic assessments to a contextual health record
Proposed topic · not yet published
How can a clinic understand what happens between assessments without confusing more measurements with better evidence?
A proposed guide to combining clinic assessments, biomarkers, wearable observations and member-reported context. It would distinguish individual trajectories from population comparisons and explain why measurement timing matters.
Look for longitudinal cohorts, clearly described measurement methods and validated instruments. Separate within-person observations from evidence of an intervention effect.
Longevity clinics · program leads · members
Workflow: Patient App → Platform → Intelligence
Explore the related workflowPharma & research
Data quality, provenance and an explicit research question
Proposed topic · not yet published
When is a connected dataset sufficiently relevant and reliable for a specific research use?
A proposed framework for pharma, biotech and evidence teams to define a question before selecting data. The emphasis is on population coverage, variable definitions, source provenance and the limits of observational interpretation—not on assuming every export is evidence.
Prioritize methods guidance and studies with explicit eligibility, ascertainment, follow-up and sensitivity analyses. Regulatory relevance depends on the intended use and applicable guidance.
Pharma & biotech · HEOR · evidence teams
Workflow: Platform → research export
Explore the related workflowPharma & research
Between-visit experience, burden and structured reporting
Proposed topic · not yet published
How can patient services capture meaningful experience without turning daily life into a reporting task?
A proposed paper on structured check-ins, patient-reported outcomes and accessible participation. It would connect program operations with patient experience while distinguishing engagement measures from validated outcomes.
Use instrument validation, patient involvement and feasibility studies. Evaluate burden and missing responses; completion alone does not demonstrate health benefit.
Patient services · program teams · patients
Workflow: Patient App → program views
Explore the related workflowPharma & research
Continuity beyond scheduled study visits
Proposed topic · not yet published
How can research teams preserve a comparable record when participation, sources and follow-up change over time?
A proposed methodology paper for sponsors and CROs on natural-history and long-term follow-up workflows. It would explain protocol alignment, versioned definitions, data reconciliation and the difference between ongoing observation and a study endpoint.
Seek natural-history protocols, registry methods and retention reporting. Small samples, changing definitions and uneven observation periods must remain visible.
CROs · sponsors · research operations
Workflow: Patient App → Platform → study review
Explore the related workflowData & governance
Connecting records without losing source meaning
Proposed topic · not yet published
What must be preserved when clinical records, labs, devices and self-reports are brought together?
A proposed technical and operational guide to source mapping, terminology, identity matching and time alignment. It would explain why exchanging a record is not the same as making its contents semantically comparable.
Prioritize official standards documentation and implementation specifications. Validate against actual source systems; standards support is not proof of an available connector.
Health systems · informatics · implementation teams
Workflow: Source systems → Platform → authorized views
Explore the related workflowData & governance
Traceable summaries, human review and evidence boundaries
Proposed topic · not yet published
How should teams evaluate an answer generated from an incomplete longitudinal record?
A proposed evaluation guide to source-linked summaries and cohort questions. It would focus on answer fidelity, missing information, access boundaries and professional review rather than presenting generated text as a clinical conclusion.
Select transparent evaluation methods, task-specific benchmarks and human review criteria. Published model performance does not establish performance in a particular deployment.
Clinical teams · research leads · governance
Workflow: Platform record → Intelligence → human review
Explore the related workflowEditorial methodology
Topics are selected for relevance to a real care or research workflow, methodological depth and a useful explanation of what the evidence can—and cannot—support.
Start with a practical question for a clinic, sponsor, CRO, health system, payer or user. Choose topics that connect a data challenge with a clear workflow and a decision someone actually needs to make.
Review author expertise, publisher, date, document version, study design and conflicts of interest. Prefer primary research, official standards and authoritative methods guidance; distinguish external evidence from company commentary.
Record population, setting, measures, follow-up and limitations beside each finding. Check denominators and uncertainty before including a benchmark. Never transfer an external study result into a Clarrio.ai performance claim.
Explain what a finding means for collection, harmonization, review and outputs. Separate implications for payers and professional teams from the experience of individual patients or members.
Check citations, wording, document rights and scientific interpretation. Publish the supplied title, authors, version and document only after review, then revisit the page when the source or product scope changes.
Reading evidence responsibly
A whitepaper may explain an approach or synthesize literature. It is not automatically peer-reviewed research, proof of product performance or a substitute for a program-specific evaluation.
Examine relevance to the population and decision, completeness of follow-up, comparators, uncertainty and reproducibility. Operational convenience and evidence strength are different dimensions.
Look for meaningful measures, understandable feedback, accessible participation and a manageable reporting burden. Group findings should not be presented as a guarantee for an individual.
Your program, your questions
Start with the population, data sources and decisions that matter to your team. Explore the relevant solution before discussing a program-specific scope.
Your next research question
Describe your research context for AI-powered workflow recommendations, sample questions, and evidence considerations.